This signal has not been consistently replicated across incretin-based therapies as a whole, and no equivalent MHRA Drug Safety Update or EMA/PRAC communication has been issued specifically for GLP-1 receptor agonists in this regard
New real-world evidence suggests that staying on GLP-1 therapy may be critical for sustaining cardiovascular protection, while even short interruptions could diminish long-term benefits in people with type 2 diabetes
Appetite changes often occur first, followed by gradual weight loss as calorie intake decreases and the body begins utilizing stored fat for energy
It is not a dietary supplement or pharmaceutical product
Additionally, patients experiencing severe vomiting or diarrhea should be monitored for dehydration and acute kidney injury
Once-weekly formulations typically provide more stable plasma concentrations with lower peak levels compared to shorter-acting preparations, potentially reducing the intensity of gastrointestinal side effects